ST
MYGN icon

Spot Trading’s Myriad Genetics MYGN Stock Holding History

Spot Trading’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,101
Closed -$23K – 3019
2016
Q3 		$23K Sell
1,101
-12,900
-92% -$327K ﹤0.01% 2790
2016
Q2 		$428K Buy
+14,001
New +$486K 0.01% 1727
2015
Q4 		– Sell
-85
Closed -$3K – 3897
2015
Q3 		$3K Hold
85
– – ﹤0.01% 3749
2015
Q2 		$3K Sell
85
-6,055
-99% -$206K ﹤0.01% 3695
2015
Q1 		$217K Buy
6,140
+6,004
+4,415% +$215K ﹤0.01% 2693
2014
Q4 		$5K Buy
+136
New +$4.83K ﹤0.01% 3760
2014
Q1 		– Sell
-86,876
Closed -$2.69M – 4397
2013
Q4 		$1.82M Sell
86,876
-140,061
-62% -$3.54M 0.01% 1555
2013
Q3 		$5.33M Buy
+226,937
New +$6.45M 0.03% 680

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Spot Trading's MYGN Position: Q4 2016 in Review

Spot Trading sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 1,101 shares — an estimated $23K sold.

Spot Trading first reported a position in MYGN in Q3 2013 and held it in 8 quarters. The position peaked at $5.33M in Q3 2013. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

  • Spot Trading reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 1,101 Myriad Genetics shares in Q4 2016, an estimated $23K.
  • Spot Trading first reported a position in Myriad Genetics in Q3 2013 and held it in 8 quarters.
  • Spot Trading's Myriad Genetics position peaked at $5.33M in Q3 2013.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.